Remyelination Advisory Board

Alasdair Coles, Ph.D.

Professor of Neuroimmunology, University of Cambridge

Dr. Coles was closely involved in the development of alemtuzumab (Campath-1H), a humanized monoclonal antibody as a treatment for MS. Alemtuzumab has received its European license and was approved by the FDA and NICE. He has also led trials of a novel remyelinating therapy in MS and of immunotherapy in autoimmune psychosis. Coles treats people with multiple sclerosis, general neurological problems and those with inflammatory diseases of the brain. He is Chair of the MS Advisory Group of the Association of British Neurologists, Chair of Cure Parkinson’s research committee and chaired the group that drew up the latest NHS England MS Treatment Algorithm.